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ABSTRACT 
 Ras proteins are important signalling hubs frequently dysregulated in cancer and in a 
group of developmental disorders called Rasopathies. Three Ras genes encode four 
proteins that differentially contribute to these phenotypes. Using quantitative real-time 
PCR (qRT-PCR) we have measured the gene expression profiles of each of the Ras 
isoforms in a panel of mouse tissues derived from a full developmental time course 
spanning embryogenesis through to adulthood. In most tissues and developmental 
stages we observe a relative contribution of KRas4B>>NRas≥KRas4A>HRas to total 
Ras expression with KRas4B typically representing 60-99% of all Ras transcripts. 
KRas4A is the most dynamically regulated Ras isoform with significant up-regulation of 
expression observed pre-term in stomach, intestine, kidney and heart. The expression 
patterns assist interpretation of the essential role of KRas in development and the 
preponderance of KRas mutations in cancer. 
 
 
INTRODUCTION 
 Ras proteins are small molecular weight GTPases that act as molecular switches 
controlling key cell proliferation and anti-apoptosis pathways 1. There are 3 ubiquitously 
expressed Ras genes encoding 4 proteins: HRas, KRas4A, KRas4B and NRas. 
Activating mutations in Ras isoforms are present in 20-30% of human cancer cases and 
in a group of developmental disorders known collectively as Rasopathies that affect as 
many as 1 in 1,000 people 2,3.  
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 Whilst the proteins encoded by the Ras genes are almost identical and with a 
common set of activators and effectors, they are not functionally redundant 4. Most 
cancer types favour mutation of a specific Ras isoform, typically KRas, for reasons that 
are still unclear 3. Isoform-specific biology is also seen amongst the Rasopathies where 
Noonan syndrome, associated with KRas and NRas, Cardiofaciocutaneous syndrome, 
associated with KRas and Costello syndrome, associated with HRas, exhibit 
overlapping but distinctive developmental and cardiovascular clinical characteristics 2. 
Finally, knockout mouse studies reveal that only KRas is essential for mouse 
development 5. Double NRas and HRas knockouts are viable and fertile whereas KRas 
knockouts die between E12.5 and birth exhibiting severe neuronal and cardiac 
abnormalities 5,6. 
 ERas is a closely related Ras family member that is only expressed during mouse 
embryogenesis 7. The gene is not generally expressed in humans but is aberrantly 
induced in gastric tumours 8,9. Unlike the other Ras isoforms, ERas is constitutively 
active and binds preferentially to PtdIns 3-kinase (PI3K) but not Raf 10. ERas knock-out 
mice were viable and without any obvious abnormalities; therefore, the precise 
contribution of ERas to early mouse development is still largely unknown 10. 
 The relative contribution of Ras isoforms to total Ras signaling remains to be 
elucidated. The predominance of KRas mutations in cancer and the essential role of 
KRas in mouse development suggests that this is the most important isoform. This is 
complicated by the fact that KRas is alternatively spliced into two isoforms KRas4A and 
KRas4B that exhibit non-redundant contributions to tumourigenesis and development 
11,12. Furthermore, the compelling observation that KRas is the only isoform required for 
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development was challenged by a study that substituted HRas into the KRas locus 13. 
These mice survived to adulthood suggesting that the spatiotemporal expression profile 
of KRas was a dominant factor in the essential role of KRas for development. To help to 
interpret these data, it is important to know the relative expression profiles of all of the 
Ras isoforms. 
 To date, analysis of Ras isoform expression has either provided semi-quantitative 
results or focused on specific isoforms in a subset of adult tissues or cell lines 14-20. An 
example is the Northern blot based analysis of HRas, KRas and NRas expression in 
mouse adult tissues and whole embryos 14. This allowed comparison of Ras expression 
between tissues but the lack of calibrated standards precluded absolute quantitation of 
the relative contributions of each isoform to total Ras transcript abundance. Similarly, 
whilst Northern blot and quantitative real-time PCR (qRT-PCR) analysis has quantified 
the dominant cell and tissue expression of KRas4B versus KRas4A (typically 
representing ~60-99% of total KRas transcripts), the other Ras isoforms were not 
compared 18,19.  
 We have used qRT-PCR to more precisely quantify the transcript copy number 
contribution for each of the Ras isoforms to total Ras expression across the major 
tissues and through a full developmental time course. Ras transcripts are highly 
abundant in all tissues with the highest expression seen in brain where Ras biology is 
virtually uncharacterized. The dominant contribution of KRas4B to total Ras expression 
may explain the major role of this isoform in cancer and development whilst the 
ubiquitous and highly dynamic pattern of KRas4A expression suggests novel biology for 
this poorly studied isoform. 
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RESULTS 
Optimising qRT-PCR for Ras isoforms 
Accurate measurement of Ras isoform expression using quantitative PCR 
necessitated the design and optimisation of PCR primers that could specifically amplify 
each of the Ras isoforms. During splicing of KRas, the difference between KRas4A and 
KRas4B is the presence or absence of the 4A exon. Since exon 4B is present in the 
untranslated region of KRas4A mRNA, we developed a reverse primer covering the 
exon 3/4B splice junction that would specifically amplify KRas4B (Figure 1A). Standard 
end-point PCR followed by agarose gel electrophoresis confirmed that single products 
of the correct size were amplified by each Ras primer pair from the cognate Ras 
plasmid (Figure 1B). No cross-amplification was seen with other Ras isoforms for any of 
the isoform-specific primer pairs. These primer pairs were also able to specifically 
amplify bands of the correct size from cDNA  (Supplementary Figure 1A). No primer 
dimers were observed under optimised qRT-PCR conditions used for subsequent tissue 
analysis (Supplementary Figure 1B). We did not identify any reference transcripts that 
were suitable for comparison across tissues and through development. We therefore 
generated standard curves for each isoform-specific PCR reaction such that we could 
then determine absolute copy number for each template as a function of the threshold 
cycle (Ct) value (Supplementary Figure 1C). These were used to determine transcript 
copy number in subsequent tissue analysis. We note that there may be differences in 
the amplification efficiency of plasmid DNA versus cDNA that may influence the final 
transcript copy number values that we obtain. However, in contrast to supercoiled 
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plasmid, amplification of linearised plasmid (as used here) has been shown to give 
similar quantitation to amplification of cDNA 21. 
 
KRas4B expression is significantly higher than the other Ras isoforms. 
We chose the outbred CD-1 mouse strain to study expression of Ras isoforms in 
normal tissues. Analogous to the case in humans, each of the Ras genes are present 
as 2 alleles in mice 22. qRT-PCR analysis of 15 adult mouse tissues revealed a range of 
total Ras expression from 5-60 copies per pg of RNA (Figure 2A, Supplementary Table 
1). Since the average cell contains ~10pg of RNA 23,24, this translates into approximately 
50-600 copies per cell making total Ras transcripts highly abundant compared to most 
other gene transcripts 25. In every tissue studied KRas4B was the most abundant 
isoform representing 70-99% of total mRNA copies (Figure 2B). In most tissues, NRas 
was the next most abundant isoform except for a tissue subset of stomach, intestine, 
lung, liver and kidney where significant KRas4A expression was observed. Expression 
of both of these isoforms ranged from 0.1-1 copy per pg of RNA in most tissues 
(Supplementary Table 1). HRas was consistently the least abundant isoform, present at 
<0.1 copies per pg of RNA (~1 mRNA copy per cell) in all tissues except brain and 
muscle (Figure 2B). For comparison, we analysed Ras abundance in undifferentiated 
R1 mouse embryonic stem cells (mESCs). Whilst KRas4B again represented the most 
abundant isoform, the early embryo-specific ERas accounted for ~20% of total Ras 
transcripts. Notably, KRas4A expression in mESCs represents <0.005% total Ras 
transcripts with fewer than 0.04 molecules per pg of RNA (<0.5 copies per cell) 
suggesting little if any contribution to early development. 
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Splicing of KRas into KRas4A and KRas4B isoforms is of interest since both 
isoforms will harbour the oncogenic mutations observed in ~20% of human cancers and 
have differential cancer promoting activities 11. KRas is frequently mutated in lung and 
intestinal cancers and both exhibit higher than average KRas4A expression 
(Supplementary Table 1) with KRas4A also contributing a higher share of total KRas 
expression in intestine (Figure 2C). Whilst previous qRT-PCR-based analysis of human 
adult tissues has suggested that KRas4A is not ubiquitiously expressed 17, we detected 
KRas4A in every tissue examined; albeit at low levels and in most cases representing 
<5% of total KRas transcripts. 
 
Spatiotemporal expression profile of Ras isoforms during development. 
We quantified the expression of Ras isoforms during each of the key stages in 
development from the embryo to the mature adult (Figure 3A). Given the small size of 
the nascent organs during embryogenesis, we pooled organs from whole litters (8-14 
individuals) for each time point for each biological repeat pre-birth. For neonates, we 
used two littermates for each time point which, together with the maternal adult, 
generated a post-birth time-course of related individuals for each biological replicate. 
Pre-birth, whole organs were pooled for analysis; post-birth, we randomly sampled each 
of the organs with the exception of brain and intestine where cerebral cortex and small 
intestine were selectively harvested. 
Contrasting patterns of Ras expression can be seen between isoforms and tissues 
during development. Whilst most tissues harbour at least one Ras isoform exhibiting 
dynamic patterns of expression, the expression of all four Ras isoforms in lung remains 
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stable throughout the ~40 day time course (Figure 3B). Here again, KRas4B is the most 
abundant transcript at each time point throughout development. The largest changes 
can be seen with KRas4A that increases 10-25-fold over the developmental time-course 
in kidney, stomach and intestine. Notably, a spike in expression around birth can also 
be seen in heart; a tissue where KRas4A has not previously been thought to be 
expressed 17. For the other isoforms there is a general trend for either stable expression 
or a decrease in expression over time that is most clearly seen with NRas (Figure 3C). 
Together, this represents the most comprehensive analysis of Ras isoform expression 
during development available, with absolute quantitation that enables relative 
contributions of Ras isoforms to total Ras transcript expression to be accurately 
determined. 
 
DISCUSSION 
 We have generated the first comparative analysis of Ras isoform gene expression in 
major tissues and at key developmental stages. In most tissues we observed a relative 
contribution of KRas4B>>NRas≥KRas4A>HRas to total Ras expression. The 
dominance of KRas4B expression (60-99% of Ras transcripts) in all tissues throughout 
all developmental stages analysed may explain the essential role of this isoform for 
viability and normal development. When considering the gene expression patterns it’s 
important to note that our data represent gross tissue measurements and do not 
account for sub-anatomical differences in Ras expression that may exist due to the 
heterogeneous cell populations present within each tissue. Similarly, we did not 
systematically analyse functional sub-regions of tissues such as the brain to explore 
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whether the expression patterns that we observed in the cerebral cortex were observed 
in other sub-regions. 
 Whilst gene expression levels do not provide mechanistic insight into Ras function, 
they remind us of some relatively neglected areas of Ras biology. For example, the 
highest levels of Ras expression were observed in the brain where KRas isoforms 
represent >99% of Ras transcripts (Figure 2). Although we do not know the relative 
contributions of neurons or associated glial cells to these values, the function of Ras in 
the central nervous system is enigmatic. KRas knockout mice and the Costello and 
Noonan syndrome Rasopathies exhibit brain stem and neurodevelopmental defects 
indicating a requirement for Ras in normal brain development 2,5. This may be linked to 
the promotion of brain stem cell proliferation by KRas 26; however, in terminally 
differentiated, non-proliferating neurons this functionality become superfluous. Instead, 
accumulating evidence suggest an important alternative signaling function for Ras in 
regulating synaptic plasticity and learning 27-31. 
 Another under-explored area of Ras biology is the function of KRas4A. Whilst 
KRas4B, HRas and NRas are ubiquitously expressed, KRas4A is generally thought to 
have a more restricted expression profile based on human tissue analysis 17. In 
contrast, in our analysis and a previous Northern blotting based screen of KRas4A 
expression it was detected in all mouse tissues studied including those where is was not 
observed in human samples (Figure 2; 16). Our data describing a bias towards KRas4B 
splicing is consistent with previous observations that KRas4B represents the majority of 
total KRas gene expression 18,19. For example, in a recent qRT-PCR-based study by the 
Mark Philips laboratory, KRAS4A was expressed at varying levels across cancer cell 
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lines derived from several tissue types and represented ≤25% of total KRAS expression 
in 25 of the 30 cell lines studied 18. Furthermore, KRAS4A represented 15-50% of total 
KRAS expression in 17 human colorectal cancer samples indicating highly context-
dependent regulation of KRAS splicing 18.  
 The reversible post-translational modifications that direct membrane localization and 
define Ras isoforms mean that KRAS4A may have the capacity to behave like KRAS4B 
or NRAS dependent on whether or not it is palmitoylated 32. Although this does not 
mean that KRas4A can substitute for the essential mouse developmental role of 
KRAS4B 12, the expression of KRAS4A was the most dynamically regulated of any of 
the Ras isoforms during development (Figure 3). The transient increase in KRas4A 
expression in the heart around birth coincides with the time when cardiac myocytes exit 
the cell cycle and undergo hypertrophy 33. The ~10-25-fold increase in KRas4A 
expression in stomach and intestine between E11.5 and birth occurs when the gut 
elongates, differentiates into a stratified epithelium and the intestinal crypt and villus 
structure develops 34. Nothing is known about the possible role of KRas4A in these 
processes; however, the gut developmental programme that includes Wnt/β-catenin 
signaling is frequently dysregulated in colorectal cancer where KRas mutations are also 
typically found 3,35.  
 The preponderance of KRas mutations in cancer has long been known but is still not 
properly understood 36. KRas mutations are frequently observed in lung, colon and 
pancreas and this is proposed to be due to the ability of KRas to promote endodermal 
stem cell expansion 37. More recently, an alternative model suggested that the relative 
expression levels of the Ras isoforms are an important factor. KRas contains a higher 
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proportion of rare codons compared to the other isoforms and this limits the translation 
efficiency of this isoform 38. Optimising the codons resulted in higher KRas protein 
expression and a reduced tumour burden consistent with previous studies that showed 
that high levels of Ras expression promote senescence rather than tumourigenesis 39,40. 
These observations lead to the proposal that rare codon restricted KRas protein 
expression in comparison with the other isoforms contributes to the extra oncogenic 
potency of KRas.  
 The notion that KRas protein expression is limited contrasts with quantitation of Ras 
isoform protein abundance in cancer cell lines where KRas was the most abundant 
isoform in the majority of cell lines 15,41. Our analysis of Ras isoform gene expression in 
normal tissues is broadly consistent with the dominance of KRas protein expression in 
cancer cell lines representing a wide range of tissues; however, the relative proportions 
are significantly different. Whilst in cell lines KRas typically represented 40-60% of total 
Ras protein abundance, we find the KRas contributes ~60-99% of total Ras transcript 
copies (Figure 2). The high KRas transcript copy number may represent a 
compensatory mechanism for overcoming rare codon influence on translation. This is 
likely to be context dependent since transfer RNA composition varies between tissues 
42,43.  
 Whilst we have not measured protein expression, the relative concentrations of Ras 
proteins within the cell are likely to be a predominant factor regulating isoform-specific 
behavior. It’s tempting to speculate that the reason why KRAS is the most important 
isoform during development and in cancer is because a high KRAS expression level 
versus the other Ras isoforms means that Ras networks more often than not initiated by 
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KRAS and therefore tuned to respond to this isoform. Clearly, gene expression levels 
do not necessarily correlate to protein abundance and absolute quantitation of Ras 
protein abundance in tissues is now required to determine if and why the mRNA levels 
of Ras isoforms are not proportional to the protein levels in tissues. This will then enable 
a detailed analysis of the potential post-transcriptional or translational regulatory 
mechanisms that may be responsible for any difference and an assessment of the role 
of rare codons in regulating KRAS expression levels and oncogenic potential.  
 In summary, we have quantified the transcript expression profiles of each of the Ras 
isoforms through a full developmental cycle from the emergence of major organs 
through to adulthood. The spatio-temporal patterns of expression highlight neglected 
areas of Ras biology and inform models that try to explain the essential role of KRas in 
development and the preponderance of KRas mutations in cancer.  
 
METHODS 
Cell culture 
 R1 mouse embryonic stem cells 44 were cultured on a feeder layer of mouse STO 
fibroblast cells 45 in high glucose DMEM containing 15% FBS, 1% L-glutamine, 0.1 mM 
non-essential amino acids, 0.01% mercaptoethanol, 260U/ml Leukemia Inhibitory 
Factor (LIF). To separate undifferentiated R1 ESCs from STO cells, the cells were 
trypsinised, replated onto dishes coated with 0.1% gelatin and allowed to adhere for 20 
minutes. The rapid adherence of STO cells versus R1 ESCs results in a non-adherent 
fraction highly enriched with R1 ESCs that were used for RNA extraction. 
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Tissue collection 
 Schedule 1 euthanasia of mice and all associated procedures and protocols were 
carried out in accordance with Home Office guidelines and regulations. All methods and 
protocols were approved by the University of Liverpool Animal Welfare and Ethical 
Review Body. Tissue from euthanised embryos, neonates and maternal adults of CD-1 
mice (Charles River) were harvested at the indicated developmental time points, 
carefully rinsed in cold PBS and snap frozen in liquid nitrogen. Whole organs from all 
littermates were pooled for pre-birth time points. Post-birth, sections of organs were 
randomly sampled with the exception of brain (cerebral cortex), intestine (small 
intestine) and muscle (hind leg skeletal muscle). Care was taken to wash away the 
associated blood and contents of heart, stomach and intestine derived from neonates 
and adults before snap freezing and storage at -80°C.  
 
Quantitative RT-PCR 
 RNA was isolated from cultured cells or fresh frozen tissue samples using the 
RNA/Protein Purification kit (Norgen). 20-50 mg of thawed tissue was homogenised in 
RNA Lysis buffer (Norgen) using a PowerLyzer (MO BIO Laboratories), transferred to 
RNAse free microfuge tubes and debris pelleted before RNA extraction. Reverse 
transcription was performed on 1 µg total RNA using RevertAid H-minus M-MuLV 
reverse transcriptase (Fermentas) and an oligodT primer (Promega); control reactions (-
RT) omitted reverse transcriptase. Quantitative real-time RT-PCR (qRT-PCR) was 
performed in triplicate (n=3 biological repeats each comprising 2 technical replicates) 
using SYBR Green Supermix (Bio-Rad) on a CFX Connect Thermal Cycler (Bio-Rad). 
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The following primers designed to generate isoform-specific Ras amplicons were used: 
ERas forward: 5’-GGTCAGATCCGCCTACTGCC-3’, reverse: 5’-
CACCACCACTGCCTTGTACTCG-3’; HRas forward: 5’-
GCTGTAGAAGCTATGACAGAATAC-3’, reverse: 5’-
GCTGTGTCTAAGATGTCCAGTAG-3’; KRas4A forward: 5’-
AGATGTGCCTATGGTCCTGGTAG-3’, reverse: 5’-
CAATCTGTACTGTCGGATCTCTCTC-3’; KRas4B forward: 5’-
GATGTGCCTATGGTCCTGGTAG, reverse: 5’-CATCGTCAACACCCTGTCTTG-3’; 
NRas forward: 5’-CAAGGACAGTTGACACAAAGC-3’, reverse: 5’-
TGTCTTACTACATCAGCACACAG-3’. Samples were amplified in a three step reaction 
with annealing at 62°C (30 s); melt curves were analysed after 40 cycles. Results were 
normalised to standard curves generated from 5-fold dilution series of the following 
linearised full-length mouse Ras isoform plasmids: pCR4-TOPO-ERas (IMAGE ID: 
8734026), pCR-Blunt II-TOPO-KRas-4A (IMAGE ID: 40052024) and pCMV-SPORT6-
KRas4B (IMAGE ID: 3158212) (Source BioScience). Full-length mouse HRas and an 
NRas fragment for standard curve generation were amplified from mouse R1 ESCs 
using the following primers: forward: 5'-GAGATCTCTATGACAGAATACAAGCTTG-3', 
reverse: 5'-ACCTCGAGATCAGGACAGCAC-3' and NRas forward: 5’-
CAAGGACAGTTGACACAAAGC-3’, reverse: 5’-TGTCTTACTACATCAGCACACAG-3’ 
and sub-cloned into pCR4-TOPO. A full-length pCMV-SPORT6-NRas plasmid (IMAGE 
ID: 6475312) (Source BioScience) was used to check for non-specific cross 
amplification. 
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FIGURE LEGENDS 
Figure 1. Specific PCR amplification of Ras isoforms. (A) Schematic of exon 
organization of Ras isoforms with coding areas in white and non-coding in black. Arrows 
indicate locations of isoform-specific Ras primer pairs. For KRas4B, the reverse primer 
was designed to span the exon3/4B splice boundary. (B) Ras isoform-specific primers 
were used in end-point PCR reactions with the indicated linearised templates of each 
Ras isoform plasmid. Products of the correct size were observed and there was no 
evidence of cross-amplification.  
SREP-16-29268-T 
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Figure 2. Quantitation of Ras isoform expression in adult tissues. (A) Total Ras 
expression summed from qRT-PCR quantitation of HRas, KRas4A, KRas4B, NRas and 
ERas. (B) Analysis of the relative expression of Ras isoforms indicates that KRas4B 
represents 70-99% of total tissue Ras mRNA transcripts. Histogram employs log scale 
to show contribution of minor isoforms.  Pie charts show the relative expression of all 
Ras isoforms except KRas4B.  (C) Contribution of KRas4A and KRas4B to total KRas 
expression. n=3 adult mice per tissue, n=3 R1 mESC cell samples. 
 
Figure 3. Ras isoform expression during development. (A) Schematic of tissue 
collection schedule during developmental stages. (B) qRT-PCR quantitation of Ras 
isoform expression in mouse tissues. (C) Comparison of expression at P30 with E11.5 
reveals dynamic changes amongst all Ras isoforms across tissues with most showing a 
decrease in Ras expression during maturation. Tukey plots depict data minima and 
maxima, the range between the first and third quartiles and the line indicates the 
median. 
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Supplementary Table 1. Ras isoform tissue expression profiles. Transcript copy 
number in adult tissues and a ten point developmental time course. 
 
Supplementary Figure 1. Specific qRT-PCR amplification and quantitation of 
Ras isoforms. (A) The correct sized products of Ras isoforms are specifically 
amplified from mESC cDNA using end-point qRT-PCR; no products are seen in 
the minus reverse transcriptase (-RT) and dH2O negative controls. (B) Melt curve 
analysis of qRT-PCR amplification products from each tissue for each Ras 
isoform show no evidence of primer dimer; melt curve for amplification from 
plasmid template shown in red. (C) qPCR analysis of 5-fold dilution series of 
plasmids for each of the Ras isoforms generated standard curves allowing 
conversion of Ct measurements into copy number values for absolute 
quantitation of Ras isoform transcript expression in tissues.  
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